Format

Send to

Choose Destination
Curr Med Chem. 2012;19(23):3907-21.

Role of PARP inhibitors in cancer biology and therapy.

Author information

1
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Abstract

Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.

PMID:
22788767
PMCID:
PMC3421454
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
Loading ...
Support Center